{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:31:20Z","timestamp":1784543480698,"version":"3.55.0"},"reference-count":54,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Duncan Family Fund"},{"name":"Cancer Fighters of Houston Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives:Cancer vaccine targets mostly include mutations and overexpressed proteins. However, cancer-associated post-translational modifications (PTMs) may also induce immune responses. Previously, our group established the enzyme protein arginine deiminase type-2 (PADI2), which catalyzes citrullination modification, is highly expressed in triple-negative breast cancer (TNBC), promoting antigenicity. Methods: Here, we show the workflow of designing citrullinated enolase 1 (citENO1) vaccine peptides identified from breast cancer cells by mass spectrometry and demonstrate TNBC vaccine efficacy in the mouse model. Immunized mice with citENO1 peptides or the corresponding unmodified peptides, plus Poly I:C as an adjuvant, were orthotopically implanted with a TNBC murine cell line. Results: Vaccination with citENO1, but not unmodified ENO1 (umENO1), induced a greater percentage of activated CD8+ PD-1+ T cells and effector memory T cells in skin-draining lymph nodes (SDLNs). Remarkably, the citENO1 vaccine delayed tumor growth and prolonged overall survival, which was further enhanced by PD-1 blockade. Conclusions: Our data suggest that cancer-restricted post-translational modifications provide a source of vaccines that induce an anti-cancer immune response.<\/jats:p>","DOI":"10.3390\/vaccines13060629","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T06:11:49Z","timestamp":1749622309000},"page":"629","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-0453","authenticated-orcid":false,"given":"Ricardo A.","family":"Le\u00f3n-Letelier","sequence":"first","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro M.","family":"Sevillano-Mantas","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"},{"name":"Therapeutic Innovation Center, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3528-6104","authenticated-orcid":false,"given":"Yihui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7797-627X","authenticated-orcid":false,"given":"Jody","family":"Vykoukal","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.","family":"Fahrmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-6539","authenticated-orcid":false,"given":"Edwin J.","family":"Ostrin","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Garrett","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhang","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chung","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-0972","authenticated-orcid":false,"given":"Jennifer B.","family":"Dennison","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-3761","authenticated-orcid":false,"given":"Eduardo","family":"Vilar","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu K.","family":"Arun","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Hanash","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3117-1390","authenticated-orcid":false,"given":"Hiroyuki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1634\/theoncologist.2017-0095","article-title":"Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field","volume":"22","author":"Yam","year":"2017","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111549","DOI":"10.1016\/j.intimp.2024.111549","article-title":"Novel immunotherapies for breast cancer: Focus on 2023 findings","volume":"128","author":"Lan","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105401","DOI":"10.1016\/j.ejps.2020.105401","article-title":"Understanding Breast cancer: From conventional therapies to repurposed drugs","volume":"151","author":"Costa","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: The next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: Building a bridge over troubled waters","volume":"185","author":"Sellars","year":"2022","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2013.01.020","article-title":"Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer","volume":"144","author":"Cappello","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vishweshwaraiah, Y.L., and Dokholyan, N.V. (2022). mRNA vaccines for cancer immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1029069"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1390642","DOI":"10.1080\/2162402X.2017.1390642","article-title":"Citrullinated alpha-enolase is an effective target for anti-cancer immunity","volume":"7","author":"Cook","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/0008-5472.CAN-15-1085","article-title":"Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity","volume":"76","author":"Brentville","year":"2016","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/0008-5472.CAN-18-2797","article-title":"Citrullination in Cancer","volume":"79","author":"Yuzhalin","year":"2019","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2174\/1389450116666150202160954","article-title":"Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation","volume":"16","author":"Witalison","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lfs.2017.08.029","article-title":"Autophagy: The spotlight for cellular stress responses","volume":"188","author":"Ravanan","year":"2017","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/cmi.2018.2","article-title":"Autophagy in dendritic cells","volume":"15","author":"Ghislat","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/imr.12422","article-title":"Autophagy proteins in antigen processing for presentation on MHC molecules","volume":"272","author":"Munz","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e002549","DOI":"10.1136\/jitc-2021-002549","article-title":"Protein citrullination as a source of cancer neoantigens","volume":"9","author":"Katayama","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.18632\/oncotarget.6798","article-title":"Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest","volume":"7","author":"Capello","year":"2016","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11098","DOI":"10.18632\/oncotarget.3572","article-title":"Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells","volume":"6","author":"Principe","year":"2015","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1002\/art.23936","article-title":"Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase","volume":"58","author":"Lundberg","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gerstner, C., Dubnovitsky, A., Sandin, C., Kozhukh, G., Uchtenhagen, H., James, E.A., R\u00f6nnelid, J., Ytterberg, A.J., Pieper, J., and Reed, E. (2016). Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted \u03b1-Enolase T Cell Epitope in Rheumatoid Arthritis. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00494"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1158\/0008-5472.CAN-15-0248","article-title":"An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis","volume":"75","author":"Katayama","year":"2015","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-019-0082-5","article-title":"A plasma protein derived TGFbeta signature is a prognostic indicator in triple negative breast cancer","volume":"3","author":"Katayama","year":"2019","journal-title":"NPJ Precis. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1021\/pr060161n","article-title":"Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae","volume":"5","author":"Zybailov","year":"2006","journal-title":"J. Proteome Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106913","DOI":"10.1016\/j.isci.2023.106913","article-title":"Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases","volume":"26","author":"Zhao","year":"2023","journal-title":"iScience"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Park, S., Sater, A.H.A., Fahrmann, J.F., Irajizad, E., Cai, Y., Katayama, H., Vykoukal, J., Kobayashi, M., Dennison, J.B., and Garcia-Manero, G. (2022). Novel UHRF1-MYC Axis in Acute Lymphoblastic Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14174262"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-1-0716-2014-4_11","article-title":"Proteomic Profiling of the Tumor Microenvironment","volume":"2435","author":"Capello","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E1555","DOI":"10.1073\/pnas.1521812113","article-title":"Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome","volume":"113","author":"Tripathi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nielsen, M., Lundegaard, C., and Lund, O. (2007). Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinform., 8.","DOI":"10.1186\/1471-2105-8-238"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/imm.12889","article-title":"Improved methods for predicting peptide binding affinity to MHC class II molecules","volume":"154","author":"Jensen","year":"2018","journal-title":"Immunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_35","first-page":"185","article-title":"Generation and analysis of Brca1 conditional knockout mice","volume":"280","author":"Deng","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kobayashi, M., Katayama, H., Irajizad, E., Vykoukal, J.V., Fahrmann, J.F., Kundnani, D.L., Yu, C.Y., Cai, Y., Hsiao, F.C., and Yang, W.L. (2020). Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers, 12.","DOI":"10.3390\/cancers12020485"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/pr100213b","article-title":"Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer","volume":"10","author":"Tomaino","year":"2011","journal-title":"J. Proteome Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2217\/imt.15.5","article-title":"Designing vaccines to prevent breast cancer recurrence or invasive disease","volume":"7","author":"Stanton","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e000560","DOI":"10.1136\/jitc-2020-000560","article-title":"Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses","volume":"8","author":"Brentville","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e006966","DOI":"10.1136\/jitc-2023-006966","article-title":"Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity","volume":"11","author":"Shah","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1038\/ncomms5674","article-title":"Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction","volume":"5","author":"Desch","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Liu, P., Zhao, L., Kroemer, G., and Kepp, O. (2023). Conventional type 1 dendritic cells (cDC1) in cancer immunity. Biol. Direct, 18.","DOI":"10.1186\/s13062-023-00430-5"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1305","DOI":"10.1002\/cti2.1305","article-title":"Type 1 conventional dendritic cells and interferons are required for spontaneous CD4(+) and CD8(+) T-cell protective responses to breast cancer","volume":"10","author":"Mattiuz","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40425-017-0295-5","article-title":"A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer","volume":"5","author":"Dillon","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1080\/14760584.2024.2397011","article-title":"Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells","volume":"23","author":"Fantini","year":"2024","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41523-024-00686-8","article-title":"BRCA genetic testing and counseling in breast cancer: How do we meet our patients\u2019 needs?","volume":"10","author":"Dubsky","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/0008-5472.CAN-03-2970","article-title":"The prognostic implication of the basal-like (cyclin E high\/p27 low\/p53+\/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer","volume":"64","author":"Foulkes","year":"2004","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djg050","article-title":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","volume":"95","author":"Foulkes","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13073-023-01262-8","article-title":"Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development","volume":"15","author":"Nikolaienko","year":"2023","journal-title":"Genome Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wang, Y., Dackus, G., Rosenberg, E.H., Cornelissen, S., de Boo, L.W., Broeks, A., Brugman, W., Chan, T.W.S., van Diest, P.J., and Hauptmann, M. (2024). Long-term outcomes of young, node-negative, chemotherapy-naive, triple-negative breast cancer patients according to BRCA1 status. BMC Med., 22.","DOI":"10.1186\/s12916-023-03233-7"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12935-023-02941-7","article-title":"Comparative efficacy and safety of PD-1\/PD-L1 inhibitors in triple negative breast cancer: A systematic review and network meta-analysis of randomized controlled trials","volume":"23","author":"Elmakaty","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/JLB.MR0618-241RR","article-title":"OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy","volume":"105","author":"Bonifaz","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41523-022-00486-y","article-title":"Immunotherapy in triple negative breast cancer: Beyond checkpoint inhibitors","volume":"8","author":"Abdou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13053-022-00242-0","article-title":"Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: A systematic review and meta-analysis","volume":"20","author":"Caramelo","year":"2022","journal-title":"Hered. Cancer Clin. Pract."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/6\/629\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:49:57Z","timestamp":1760032197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/6\/629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["vaccines13060629"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13060629","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}